Close this search box.

Sensus Healthcare, Inc. Announces Commencement of Public Offering of Common Stock

September 12, 2018

BOCA RATON, Fla., Sept. 12, 2018 Sensus Healthcare, Inc. (Nasdaq: SRTS) announced today that it commenced a public offering of its common stock, par value $0.01 per share.

B. Riley FBR is serving as the lead underwriter and sole book-running manager for the offering. Sensus intends to use the net proceeds from the offering primarily for general corporate purposes, which may include research and development activities, expansion of its product lines and roll-out of new product offerings, capital expenditures, selling, general and administrative costs, facilities expansion, and to meet working capital needs. In addition, Sensus intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering.

The offering will be made only by means of a prospectus supplement and an accompanying prospectus filed as part of an effective shelf registration statement filed with the Securities and Exchange Commission on Form S-3.

Copies of the prospectus supplement and the accompanying prospectus relating to this offering, when available, may be obtained from B. Riley FBR at 1300 North 17th Street, Suite 1400, Arlington, VA 22209 or by calling (703) 312 9580 or by emailing [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Sensus Healthcare, Inc.

Sensus Healthcare, Inc. is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit


LHA Investor Relations
Kim Sutton Golodetz
(212) 838-3777
[email protected]

Cision View original content:

SOURCE Sensus Healthcare, Inc.